secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0000950170-24-031441
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma reports FY2023 cash $101.7M; Phase 3 sarcoidosis study enrollment to complete Q2 2024
--------------------------------------------------------------------------------

- Cash, equivalents, restricted cash, investments at Dec 31, 2023: $101.7M; cash runway through BLA filing.
- Phase 3 EFZO-FIT study in pulmonary sarcoidosis enrollment expected to complete Q2 2024; DSMB allowed unmodified continuation.
- Launched Individual Patient Expanded Access Program for patients completing EFZO-FIT study.
- Phase 2 EFZO-CONNECT study in SSc-ILD enrolling (proof-of-concept, up to 25 patients); multiple U.S. sites open.
- R&D expenses $42.3M, G&A $13.0M for year 2023; no product revenue as clinical-stage biotech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024031441/0000950170-24-031441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024031441/life-20240314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-031441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer